Litcius/Paper detail

Willingness to receive a booster dose of inactivated coronavirus disease 2019 vaccine in Taizhou, China

Tao‐Hsin Tung, Xiaoqing Lin, Yan Chen, Meixian Zhang, Jiansheng Zhu

2021Expert Review of Vaccines46 citationsDOI

Abstract

PURPOSE: This population-based study aimed to determine the willingness to receive a booster dose of vaccine against coronavirus disease (COVID-19) in Taizhou, China. METHODS: An online questionnaire investigation addressing participants' willingness to receive a booster dose of the COVID-19 vaccine was organized in Taizhou, China. Of the 2318 interviewees who received the invitation, 1576 finished a qualifying questionnaire, corresponding to a response rate of 68.0%. RESULTS: = 1435 [91.1%]) were willing to accept a booster vaccination against COVID-19. History of allergic reaction to other vaccines (OR = 0.30), confidence in the safety of the COVID-19 vaccines (OR = 3.20), confidence in the effectiveness of the COVID-19 vaccines against SARS-CoV-2 (OR = 2.25) and its variants (useful versus [vs.] useless, OR = 2.33), and vaccine recipients (OR = 3.09) remained significantly associated with willingness to accept a booster dose of COVID-19 vaccines. CONCLUSION: A moderate proportion of the participants who responded were willing to receive a booster dose of the COVID-19 vaccine. These results are valuable for starting health education and interventions to accelerate vaccine uptake and improve public health outcomes during the COVID-19 pandemic in China.

Topics & Concepts

Booster (rocketry)Booster doseMedicineVaccinationCoronavirus disease 2019 (COVID-19)PandemicConfidence intervalPopulationPsychological interventionChinaEnvironmental healthFamily medicineDiseaseVirologyImmunologyInfectious disease (medical specialty)ImmunizationInternal medicineNursingImmune systemPolitical scienceLawPhysicsAstronomySARS-CoV-2 and COVID-19 ResearchVaccine Coverage and HesitancyImmune responses and vaccinations
Willingness to receive a booster dose of inactivated coronavirus disease 2019 vaccine in Taizhou, China | Litcius